This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
IDEXX (IDXX) Business Faces Macroeconomic Woes, FX Headwinds
by Zacks Equity Research
IDEXX's (IDXX) supply chain operations bear the brunt of geopolitical instability, including the current war in Ukraine.
Inspira (IINN) Unveils Business Targets for 2024-25
by Zacks Equity Research
Inspira (IINN) discloses business goals for 2024-25 with the rapid promotion of INSPIRA ART100 and the development of INSPIRA ART (Gen 2).
Quest Diagnostics (DGX) Gains From New M&As Amid Competition
by Zacks Equity Research
In Physician Lab Services, Quest Diagnostics (DGX) is benefiting from the broad-based return to care, overall market growth and share gains driven by the competitive strength of its scale and innovative offerings.
Is Acrivon Therapeutics, Inc. (ACRV) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Acrivon Therapeutics, Inc. (ACRV) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.
Insulet (PODD) Unveils Key Achievements for the Omnipod 5 System
by Zacks Equity Research
Insulet (PODD) debuts the Omnipod 5 AID system in France and announces new updates for the U.S. markets.
Is It Wise to Hold Bio-Rad (BIO) Stock in Your Portfolio Now?
by Zacks Equity Research
Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segment raise optimism. However, macro issues raise concerns.
Thermo Fisher (TMO) Unveils New Research Laboratory in WI
by Zacks Equity Research
Thermo Fisher (TMO) announces a new 72,500-square-foot clinical research laboratory building at its good manufacturing practices lab in Middleton, WI
Thermo Fisher's (TMO) New Buyouts Aid Growth, FX Issues Stay
by Zacks Equity Research
Thermo Fisher's (TMO) business strategy primarily includes expansion through strategic acquisition of technologies and businesses that augment the company's existing products and services.
Haemonetics (HAE) Expands VASCADE Line With New Limited Launch
by Zacks Equity Research
Haemonetics (HAE) expands its VASCADE portfolio with the limited market release of VASCADE MVP XL vascular closure device.
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Boston Scientific (BSX) to Buy Silk Road, Boost Cardiology
by Zacks Equity Research
This acquisition is expected to enhance Boston Scientific's (BSX) market position and revenue streams in North America and Europe.
QIAGEN's (QGEN) New QCI Interpret Release Enhances AI Functions
by Zacks Equity Research
QIAGEN's (QGEN) latest QCI Interpret release improves the performance of high-throughput NGS labs.
Quest Diagnostics' (DGX) New Buyout Ramps Up Cancer Diagnosis
by Zacks Equity Research
Quest Diagnostics (DGX) completes the acquisition of PathAI Diagnostics, accelerating the adoption of AI and digital pathology to improve cancer diagnosis.
Hims & Hers Health, Inc. (HIMS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $24.15, indicating a +1.68% shift from the previous trading day.
QIAGEN (QGEN) Debuts dPCR Microbial DNA Detection Assays
by Zacks Equity Research
QIAGEN (QGEN) launches new QIAcuity dPCR assays for microbial applications, enhancing infectious disease research and surveillance.
STERIS (STE) Gains From New Offerings, Macro Issues Ail
by Zacks Equity Research
STERIS' (STE) AST successfully offers a wide range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.
BrainsWay (BWAY) to Advance in DEEP TMS for MDD With New Trial
by Zacks Equity Research
BrainsWay (BWAY) emphasizes the potential of the accelerated protocol, citing previous data suggesting comparable outcomes with traditional, longer protocols.
Zimmer Biomet (ZBH) Advances in GenAI Technology With RevelAi
by Zacks Equity Research
Zimmer Biomet (ZBH) and RevelAi Health have joined forces to solve social and clinician problems by commercializing RevelAi's patient care-management platform and care team dashboard for providers.
Thermo Fisher's (TMO) New Launch Supports Full Lab Automation
by Zacks Equity Research
Thermo Fisher's (TMO) first-of-its-kind innovation for CO2 incubators supports emerging automated cell therapy production processes.
Zimmer Biomet (ZBH) to Broaden Knee Surgery Line With New Alliance
by Zacks Equity Research
Zimmer Biomet (ZBH) joins forces with Think Surgical for the distribution of customized TMINI - Miniature Robotic System in the U.S. market.
Haemonetics (HAE) Banks on Growing Plasma Arm, Innovation
by Zacks Equity Research
Haemonetics (HAE) is gaining from the newly completed limited market release of the new Express Plus technology with more than 60,000 real-world collections.
Neogen's (NEOG) MDS Secures New Contract From USDA FSIS
by Zacks Equity Research
Neogen's (NEOG) MDS gets recognized by the USDA FSIS as the primary method for the detection of Salmonella and Listeria monocytogenes testing for meat, poultry and egg products.
Is Insulet (PODD) Stock an Apt Pick for Your Portfolio Now?
by Zacks Equity Research
The robust performance of Insulet's (PODD) Omnipod 5 raises investors' optimism. However, concerns remain over the macroeconomic impacts and the company's overdependence on a single platform.
Illumina (ILMN) Advances in NGS With DRAGEN v4.3 Launch
by Zacks Equity Research
One of the standout features of Illumina's (ILMN) DRAGEN v4.3 is its machine-learning mosaic model.
Abbott's (ABT) AVEIR DR Leadless Pacemaker System Gains CE Mark
by Zacks Equity Research
Abbott (ABT) receives a CE mark for AVEIR DR, the world's first dual chamber leadless pacemaker system.